eluxadoline IBS-D
Selected indexed studies
- ▼ Eluxadoline for IBS-D. (Drug Ther Bull, 2017) [PMID:28808081]
- Safety of Eluxadoline in Patients With IBS-D Without a Gallbladder. (Am J Gastroenterol, 2017) [PMID:28978951]
- Τ Eluxadoline for IBS-D. (Drug Ther Bull, 2017) [PMID:28808082]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- A Review of Pharmacologic and Non-Pharmacologic Therapies in the Management of Irritable Bowel Syndrome: Current Recommendations and Evidence. (2024) pubmed
- ▼ Eluxadoline for IBS-D. (2017) pubmed
- Safety of Eluxadoline in Patients With IBS-D Without a Gallbladder. (2017) pubmed
- Τ Eluxadoline for IBS-D. (2017) pubmed
- Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility. (2022) pubmed
- AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea. (2022) pubmed
- Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use. (2017) pubmed
- Effects of treatment with eluxadoline on abdominal pain in patients with IBS-D: Additional post hoc analyses of Phase 3 trials. (2020) pubmed
- Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials. (2019) pubmed
- Eluxadoline: First Global Approval. (2015) pubmed